281 related articles for article (PubMed ID: 31588679)
1. Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma.
Yu JI; Lee SJ; Lee J; Lim HY; Paik SW; Yoo GS; Choi C; Park HC
Cancer Med; 2019 Nov; 8(16):6986-6994. PubMed ID: 31588679
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
Yau T; Hsu C; Kim TY; Choo SP; Kang YK; Hou MM; Numata K; Yeo W; Chopra A; Ikeda M; Kuromatsu R; Moriguchi M; Chao Y; Zhao H; Anderson J; Cruz CD; Kudo M
J Hepatol; 2019 Sep; 71(3):543-552. PubMed ID: 31176752
[TBL] [Abstract][Full Text] [Related]
3. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
Cho JY; Paik YH; Park HC; Yu JI; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2014 May; 34(5):795-801. PubMed ID: 24350564
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
Kambhampati S; Bauer KE; Bracci PM; Keenan BP; Behr SC; Gordan JD; Kelley RK
Cancer; 2019 Sep; 125(18):3234-3241. PubMed ID: 31154669
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.
Lee CH; Lee YB; Kim MA; Jang H; Oh H; Kim SW; Cho EJ; Lee KH; Lee JH; Yu SJ; Yoon JH; Kim TY; Kim YJ
Clin Mol Hepatol; 2020 Jul; 26(3):328-339. PubMed ID: 32460459
[TBL] [Abstract][Full Text] [Related]
6. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients.
Marinelli B; Cedillo M; Pasik SD; Charles D; Murthy S; Patel RS; Fischman A; Ranade M; Bishay V; Nowakowski S; Sung M; Marron T; Lookstein R; Schwartz M; Kim E
J Vasc Interv Radiol; 2020 Nov; 31(11):1729-1738.e1. PubMed ID: 33012649
[TBL] [Abstract][Full Text] [Related]
8. Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization.
Chia-Hsien Cheng J; Chuang VP; Cheng SH; Lin YM; Cheng TI; Yang PS; Jian JJ; You DL; Horng CF; Huang AT
Int J Cancer; 2001 Aug; 96(4):243-52. PubMed ID: 11474499
[TBL] [Abstract][Full Text] [Related]
9. Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion.
Lee D; Lee HC; An J; Shim JH; Kim KM; Lim YS; Chung YH; Lee YS
Clin Mol Hepatol; 2018 Jun; 24(2):144-150. PubMed ID: 29665630
[TBL] [Abstract][Full Text] [Related]
10. A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma.
Choi C; Koom WS; Kim TH; Yoon SM; Kim JH; Lee HS; Nam TK; Seong J
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1051-60. PubMed ID: 25303890
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers.
Finkelmeier F; Czauderna C; Perkhofer L; Ettrich TJ; Trojan J; Weinmann A; Marquardt JU; Vermehren J; Waidmann O
J Cancer Res Clin Oncol; 2019 Jan; 145(1):253-259. PubMed ID: 30374657
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
Yoon SM; Ryoo BY; Lee SJ; Kim JH; Shin JH; An JH; Lee HC; Lim YS
JAMA Oncol; 2018 May; 4(5):661-669. PubMed ID: 29543938
[TBL] [Abstract][Full Text] [Related]
13. Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma.
Byun HK; Kim HJ; Im YR; Kim DY; Han KH; Seong J
Radiother Oncol; 2019 Apr; 133():1-8. PubMed ID: 30935563
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
[TBL] [Abstract][Full Text] [Related]
16. The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma.
Smith WH; Law AS; Hulkower M; McGee HM; Lehrer EJ; Schwartz M; Taouli B; Sung M; Buckstein M
Acta Oncol; 2020 Aug; 59(8):940-943. PubMed ID: 32441551
[No Abstract] [Full Text] [Related]
17. The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study.
Wada Y; Takami Y; Matsushima H; Tateishi M; Ryu T; Yoshitomi M; Matsumura T; Saitsu H
Intern Med; 2018 May; 57(10):1345-1353. PubMed ID: 29279513
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Chen L; Su H; Shao H; Xu K; Liang S; Liu J
Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
20. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab.
Kim N; Yu JI; Park HC; Yoo GS; Choi C; Hong JY; Lim HY; Lee J; Choi MS; Lee JE; Kim K
Cancer Immunol Immunother; 2021 Jun; 70(6):1593-1603. PubMed ID: 33231725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
